Mallinckrodt to settle opioid claims for $1.6 billion, generic unit to file Chapter 11

By Saumya Joseph

(Reuters) – Drugmaker Mallinckrodt Plc (N:) said on Tuesday its specialty generic unit will file for bankruptcy protection as it agreed to settle opioid-related cases globally by paying $1.6 billion over eight years.

The settlement was reached with a court-appointed plaintiffs’ executive committee that represents thousands of plaintiffs in the multi-district opioid litigation.

The Wall Street Journal newspaper first reported the settlement and the chapter 11 filing for Mallinckrodt’s generic unit on Monday.

Since last year, the company has been working to separate its generics unit and has said it was considering several options.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.